Revenue Update on Opexa Therapeutics Inc(NASDAQ:OPXA)

Opexa Therapeutics Inc(NASDAQ:OPXA) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $726.292K. Analysts estimated a revenue of $730.000K. The revenues were -0.51% below the estimates. Earnings per share were $-0.24. The reported EPS was above estimates by 4%. Analysts had estimated an EPS of $-0.25.

Opexa Therapeutics Inc (OPXA) shares turned negative on Fridays trading session with the shares closing down -0.0421 points or -5.18% at a volume of 1,34,363. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.8013. The peak price level was also seen at $0.8013 while the days lowest was $0.75. Finally the shares closed at $0.77. The 52-week high of the shares is $4.9299 while the 52-week low is $0.5. According to the latest information available, the market cap of the company is $5.5 M.

Several Insider Transactions has been reported to the SEC. On Nov 22, 2016, Timothy C Barabe (director) sold 14,914 shares at $0.55 per share price.

Opexa Therapeutics Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology. It is engaged in the field of Precision Immunotherapy. The Company’s product candidates include Tcelna and OPX-212. Tcelna and OPX-212 are not approved by the United States Food and Drug Administration (FDA) or other global regulatory agencies for marketing. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. In addition to the Company’s ongoing clinical development of Tcelna the Company is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Add Comment